| 1997年03月 |
BioMarin was founded in Novato, California, with an initial focus on leveraging its proprietary enzyme technology to develop therapies for genetic conditions and other diseases. |
| 1997年12月 |
BioMarin initiated its first clinical trial to evaluate a potential treatment a form of mucopolysaccharidosis. |
| 1999年07月 |
BioMarin completed its initial public offering. Since a large number of early investors were based in Europe, the company was listed on both the Swiss SWX Exchange and the Nasdaq National Market. |
| 2003年04月 |
The FDA granted marketing authorization for BioMarin’s enzyme replacement therapy for the treatment of a form of mucopolysaccharidosis. The medicine was approved in Europe that June. |
| 2005年05月 |
BioMarin’s Board of Directors elected Jean-Jacques Bienaimé as the company’s Chief Executive Officer, a role he would hold for more than 18 years. |
| 2005年05月 |
The FDA approved BioMarin’s first independently developed and commercialized medicine, and the first authorized treatment for a second form of mucopolysaccharidosis. |
| 2006年 |
The company established BioMarin Europe Ltd., headquartered in London, initially with offices in Spain, Switzerland and Italy. The company now operates in more than 70 countries around the world. |
| 2007年12月 |
The FDA approved the first therapy for the treatment of a rare metabolic condition. |
| 2011年 |
The company completed the purchase of a manufacturing facility in Shanbally, Ireland, and in November, the FDA approved the expansion of BioMarin’s biologics manufacturing facility in Novato, California. |
| 2013年02月 |
BioMarin announced it had licensed the program from University College London and St. Jude Children’s Research Hospital. This would lead to a product approval approximately 10 years later. |
| 2014年02月 |
The FDA approved BioMarin’s therapy for the treatment of another form of mucopolysaccharidosis. |
| 2016年 |
Expanding on its decade-long track record of supporting eligible people with rare diseases in gaining access to the company’s medicines, the BioMarin RareConnections program consolidated these efforts under one expanded program for people in the United States. |
| 2017年04月 |
The FDA approved BioMarin’s medicine for the treatment of an ultra-rare form of Batten disease. |
| 2018年05月 |
The FDA approved the first enzyme replacement therapy to target the underlying cause of a rare metabolic condition. |
| 2021年11月 |
Therapy for a Form of Skeletal Dysplasia Approved |
| 2022年08月 |
The European Commission approved BioMarin’s first gene therapy for the treatment of an inheritable bleeding disorder. |
| 2023年06月 |
The FDA approved BioMarin’s gene therapy for the treatment of an inheritable bleeding disorder. |
| 2023年12月 |
With the retirement of longtime BioMarin CEO Jean-Jacques Bienaimé, Alexander Hardy was named President and Chief Executive Officer. |
| 2024年07月 |
The expanded indication included children of all ages living with the ultra-rare form of Batten disease, enabling even younger children to receive the only available treatment for this debilitating and ultimately fatal condition. |
| 2025年07月 |
The acquisition strengthened BioMarin’s enzyme therapies portfolio, adding a late-stage investigational enzyme replacement therapy for ENPP1 deficiency. |
| 2026年02月 |
The FDA approved BioMarin’s supplemental Biologics License Application to include people 12 years of age and older living with a rare metabolic condition. |
| 2026年04月 |
The acquisition added two new treatments for rare lysosomal storage diseases to the company’s commercial portfolio, opening up more possibilities for people living with the conditions around the world to access therapy due to BioMarin’s global footprint. |
